Amyotrophic lateral sclerosis: Toxins and environment

Amyotrophic Lateral Sclerosis

Volumn 1, Issue 4, 2000, Pages 235-250

  Mitchell, J D ^a  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

amyotrophic lateral sclerosis; environment; genetics; motor neuron disease; toxins

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; DANGEROUS GOODS; GENETICS; HUMAN; REVIEW; RISK FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; HAZARDOUS SUBSTANCES; HUMANS; RISK FACTORS;

EID: 0034281085     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820050515061     Document Type: Review

References (135)

1. Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995; 32: 290-292.
2. Al-Chalabi A, Andersen PM, Chioza B, et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder; evidence for a linked protective factor. Hum Mol Genet 1998; 7: 2045-2050. (Pubitemid 28546412)
3. Robberecht W, Aguirre T, Van den Bosch L, et al. D90A het-erozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology 1996; 47: 1336-1339. (Pubitemid 26374913)
4. Ceroni M, Malaspina A, Poloni TE, et al. Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation. Neurology 1999; 53: 1064-1071. (Pubitemid 29442124)
5. Orrell RW, Habgood J, Rudge P, et al. Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis. Ann Neurol 1996: 39: 810-812. (Pubitemid 26183820)
6. Neilson S, Robinson I. Cross-sectional Gompertzian analysis: the development of a Gompertz mortality ratio (GMR) and its applicability. Mech Ageing Dev 1993; 68: 137-149.
7. Neilson S, Robinson I. Reinterpreting mortality statistics: some uses of Gompertzian analysis in epidemiological research. J Clin Epidemiol 1993; 46: 1063-1069. (Pubitemid 23258905)
8. Martyn CN. Epidemiology. In: Williams AC, ed. Motor Neuron Disease. London: Chapman & Hall, 1994: 393-426.
9. Bettoni L, Bazzani M, Bortone E, Dascola I, Pisani E, Mancia D. Steadiness of amyotrophic lateral sclerosis in the province of Parma, Italy, 1960-1990. Acta Neurol Scand 1994; 90: 276-280. (Pubitemid 24321503)
10. The Scottish Motor Neuron Disease Research Group. The Scottish motor neuron disease register: a prospective study of adult motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989. J Neurol Neurosurg Psychiatry 1992; 55: 536-541.
11. Gunnarsson LG, Bodin L, Soderfeldt B, Axelson O. A case control study of motor neurone disease: its relation to heri-tability, and occupational exposures, particularly to solvents. Br J Ind Med 1992; 49: 791-798.
12. Strickland D, Smith SA, Dolliff G, Goldman L, Roelofs RI. Amyotrophic lateral sclerosis and occupational history. A pilot case control study. Arch Neurol 1996: 53: 730-733.
13. Rosati G, Pinna L, Granieri E, et al. Studies on epidemiological, clinical and etiological aspects of ALS disease in Sardinia, Southern Italy. Acta Neurol Scand 1977; 55: 231-244. (Pubitemid 8046766)
14. Holloway SM, Emery AEH. The epidemiology of motor neuron disease in Scotland. Muscle & Nerve 1982; 5: 131-133. (Pubitemid 12135484)
15. Giagheddu M, Puggoni G, Masala C, et al. Epidemiologic study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol Scand 1983; 68: 394-404. (Pubitemid 14214460)
16. Armon C, Kurland LT, Daube JR, O'Brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991; 41: 1077-1084.
17. Gunnarsson LG, Lindberg G, Soderfeldt B, Axelson O. Amy-otrophic lateral sclerosis in Sweden in relation to occupation. Acta Neurol Scand 1991; 83: 394-398.
18. Gunnarsson LG, Lygner PE, Veiga-Cabo J, de Pedro-Cuesta J. An epidemic-like cluster of motor neuron disease in a Swedish county during the period 1973-1984. Neuroepide-miology 1996; 15: 142-152. (Pubitemid 26157787)
19. McGuire V, Longstreth WT, Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol 1997; 145: 1076-1088. (Pubitemid 27272937)
20. Panse F. Electrical lesions of the nervous system. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology Vol. 7. Amsterdam: North Holland, 1970: 344-387.
21. Holbrook LA, Beach FXM, Silver JR. Delayed myelopathy: a rare complication of severe electrical burns. Br Med J 1970; iv: 659-660.
22. Farrell DF, Starr A. Delayed neurological sequelae of electrical injuries. Neurology 1968; 18: 601-606.
23. Panse F. Die Schädigungen des Nervensystems durch technische Elektrizität. Monatschr Psychiat Neurol 1931; 78: 193-221.
24. Haynal A, Regli F. Zusammenhang der amyotrophischen lateralsklerose mit gehaüften Elektrotraumata. Confin Neurol 1964; 24: 189-198.
25. Gawel M, Zaiwalla A, Rose FC. Antecedent events in motor neuron disease. J Neurol Neurosurg Psychiatry 1983; 46: 1041-1043. (Pubitemid 14245020)
26. Deapen BM, Henderson BE. A case control study of amyotrophic lateral sclerosis. Am J Epidemiol 1986; 123: 790-799. (Pubitemid 16049236)
27. Nelson LM. Epidemiology of ALS. Clin Neurosci 1995-96; 3: 327-331.
28. Johansen C, Olsen JH. Mortality from amyotrophic lateral sclerosis, other chronic disorders, and electric shocks among utility workers. Am J Epidemiol 1998; 148: 362-368. (Pubitemid 28381368)
29. Savitz DA, Checkoway H, Loomis, DP. Magnetic ield exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology 1998; 9: 398-404. (Pubitemid 28298361)
30. Kondo K, Tsubaki T. Case-control studies of motor neuron disease: association with mechanical injuries. Arch Neurol 1981; 38: 220-226. (Pubitemid 11151040)
31. Neilson S, Robinson I, Clifford Rose F. Mortality from motor neuron disease in Japan, 1950-1990: association with radioactive fallout from atmospheric weapons testing. J Neurol Sci 1995; 134: 61-66.
32. Neilson S, Robinson I, Clifford Rose F. Ecological correlates of motor neuron disease mortality: a hypothesis concerning an epidemiological association with radon gas and gamma exposure. J Neurol 1996; 243: 329-336. (Pubitemid 26099504)
33. Campbell AMG, Williams ER, Barltrop D. Motor neurone disease and exposure to lead. J Neurol Neurosurg Psychiatry 1970; 33: 877-885.
34. Cresham LS, Molgaard CA, Colbeck AL, et al. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case control study. Neuroepidemiology 1986; 5: 29-38. (Pubitemid 16057165)
35. Rosati C, Pinna L, Cranieri E, et al. Studies on epidemiological, clinical and etiological aspects of ALS disease in Sardinia, Southern Italy. Acta Neurol Scand 1977; 55: 231-244. (Pubitemid 8046766)
36. Kurland LT, Radhakrishnan K, Smith CE, et al. Mechanical trauma as a risk factor in classic amyotrophic lateral sclerosis: lack of epidemiological evidence. J Neurol Sci 1992; 113: 133-143. (Pubitemid 23000561)
37. Longstreth WT, Nelson LM, Koepsell TD, van Belle C. Hypotheses to explain the association between vigorous physical activity and amyotrophic lateral sclerosis. Med Hypotheses 1991; 34: 144-148.
38. Hastings KEM. Cene expression in motor neurons. In: Smith RA, ed. Handbook of Amyotrophic Lateral Sclerosis. New York: Marcel Dekker, 1992: 709-737.
39. Kanter M. Free radicals, exercise and antioxidant supplementation. Proc Nutr Soc 1998; 57: 9-13. (Pubitemid 128736190)
40. Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999; 18: 194-202. (Pubitemid 29284080)
41. Harnisch R, Dworsky RL, Henderson BE. A search for clues to the cause of amyotrophic lateral sclerosis. Arch Neurol 1976; 33: 456-457.
42. Hawkes CH, Fox J. Motor neurone disease in leather workers. Lancet 1981; i: 507.
43. Buckley J, Warlow C, Smith P, et al. Motor neuron disease in England and Wales, 1959-1979. J Neurol Neurosurg Psychiatry 1983; 46: 197-205. (Pubitemid 13110485)
44. Holloway SM, Mitchell JD. Motor neurone disease in the Lothian region of Scotland 1961-81. J Epidem Commun Health 1986; 40: 344-350. (Pubitemid 17190137)
45. Hawkes CH, Cavanagh JB, Fox AJ. Motoneuron disease: a disorder secondary to solvent exposure? Lancet 1989; i: 73-76. (Pubitemid 19033996)
46. Chancellor AM, Slattery JM, Fraser H, et al. Risk factors for motor neuron disease: a case- control study based on patients from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1993; 56: 1200-1206. (Pubitemid 23323660)
47. Waldron HA. Lead poisoning in the ancient world. Med Hist 1973; 17: 391-399.
48. Romberg MH. Lehrbuch der Nervenkrankheiten des Menschen (2nd edn). (Originally published Berlin: Duncker) Trans & ed. Sieveking (1853), London: Sydenham Society, 1851: 371-375.
49. Bell C. The nervous system of the human body. (3rd edn). London: Longmans, 1836, 432-434.
50. Aran FA. Recherches sur une maladie non encore décrite du systeme musculaire. Arch Cen Med (4me Ser) 1850; 24: 1-35.
51. Wilson SAK. The amyotrophy of chronic lead poisoning: amyotrophic lateral sclerosis of toxic origin. Rev Neurol Psychiatry 1907; 5: 441-455.
52. Currier RD, Haerer AF. Amyotrophic lateral sclerosis and metallic toxins. Arch Environ Health 1968; 17: 712-719.
53. Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis Neurology 1976; 26: 176-172.
54. Pierce Ruhland R, Patten BM. Repeat study of antecedent events in motor neurone disease. Ann Clin Res 1981; 13: 102-107.
55. Roelofs-Iverson RA, Mulder DW, Elveback LR, et al. ALS and heavy metals: a pilot case control study. Neurology 1984; 34: 393-395. (Pubitemid 14173228)
56. Scarpa M, Colombo A, Panzetti P, Sorgato P. Epidemiology of amyotrophic lateral sclerosis in the province of Modena, Italy. Influence of environmental exposure to lead. Acta Neurol Scand 1988; 77: 456-460.
57. Guidetti D, Bondavalli M, Sabadini R, et al. Epidemiological survey of amyotrophic lateral sclerosis in the province of Reggio Emilia, Italy: inluence of environmental exposure to lead. Neuroepidemiology 1996; 15: 301-312. (Pubitemid 26356749)
58. Conradi S, Ronnevi LO, Vesterberg O. Increased plasma levels of lead in amyotrophic lateral sclerosis compared to controls as measured by lameless atomic absorption spec-trophotometry. J Neurol Neurosurg Psychiatry 1978; 41: 389-393. (Pubitemid 8323891)
59. Conradi S, Ronnevi LO, Vesterberg O. Abnormal tissue distribution of lead in amyotrophic lateral sclerosis. J Neurol Sci 1976; 29: 259-265.
60. Conradi S, Ronnevi LO, Nise G, et al. Abnormal distribution of lead in amyotrophic lateral sclerosis. Reestimation of lead in the cerebrospinal luid, J Neurol Sci 1980; 48: 413-418. (Pubitemid 11216880)
61. House AO, Abbot RJ, Davidson DLW, et al. Response to penicillamine of lead concentrations in CSF and blood of patients with motor neurone disease. Br Med J 1978; ii: 1684. (Pubitemid 9093549)
62. Stober T, Stelte W, Kunze K. Lead concentrations in blood, plasma, erythrocytes and cerebrospinal luid in amy-otrophic lateral sclerosis J Neurol Sci 1983; 61: 21-26. (Pubitemid 13000619)
63. Petkau A, Sawatzky A, Hillier CR, et al. Lead content of neu-romuscular tissue in amyotrophic lateral sclerosis - case report and other considerations. Br J Indust Med 1974; 31: 275-287.
64. Conradi S, Ronnevi LO, Vesterberg O. Lead concentration in skeletal muscle in amyotrophic lateral sclerosis patients and control subjects. J Neurol Neurosurg Psychiatry 1978; 41: 1001-1004. (Pubitemid 9010098)
65. Kurlander HM, Patten BM. Metals in spinal cord tissue of patients dying of motor neuron disease. Ann Neurol 1979; 6: 21-24.
66. Mandybur TI, Cooper GP. Increased spinal cord lead content in amyotrophic lateral sclerosis - possibly a secondary phenomenon. Med Hypotheses 1979; 5: 1313-1315. (Pubitemid 10137969)
67. Campbell AMG. Calcium versenate in motor neurone disease. Lancet 1955; ii: 376-377.
68. Simpson JA, Seaton DA, Adams JF. Response to treatment with chelating agents of anaemia, chronic encephalopathy and myelopathy due to lead poisoning. J Neurol Neurosurg Psychiatry 1964; 27: 536-541.
69. Livesley B, Sissons SE. Chronic lead intoxication mimicking motor neurone disease. Br Med J 1968; iv: 387-388.
70. Conradi S, Ronnevi LO, Nise G, et al. Long-time penicillamine treatment in amyotrophic lateral sclerosis with parallel determinations of lead in blood, plasma and urine. Acta Neurol Scand 1982; 65: 203-211. (Pubitemid 12185291)
71. Brown IA. Chronic mercurialism - a cause of the clinical syndrome of amyotrophic lateral sclerosis. Arch Neurol Psychiatry 1954; 72: 674-681.
72. Kantarjian AD. A syndrome clinically resembling amy-otrophic lateral sclerosis following chronic mercurialism. Neurology 1961; 11: 639-644.
73. Barber TE. Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. J Occup Med 1978; 20: 667-669. (Pubitemid 9035391)
74. Adams CR, Ziegler DK, Lin JT. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 1983; 250: 642-643. (Pubitemid 13078825)
75. Kilness AW, Hochberg FH. Amyotrophic lateral sclerosis in a high selenium environment. JAMA 1977; 237: 2843-2844. (Pubitemid 8140819)
76. Norris FH, U KS. Amyotrophic lateral sclerosis and low urinary selenium levels. JAMA 1978; 239: 404.
77. Nagata H, Miyata S, Nakamura S, et al. Heavy metal concentrations in blood cells in patients with amyotrophic lateral sclerosis. J Neurol Sci 1985; 67: 173-178. (Pubitemid 15130759)
78. Larsen NA, Pakkenberg H, Damsgaard E, et al. Topographical distribution of arsenic, manganese and selenium in the normal human brain. J Neurol Sci 1979; 42: 407-416. (Pubitemid 9188019)
79. Larsen NA, Pakkenberg H, Damsgaard E, et al. Distribution of arsenic, manganese and selenium in the human brain in chronic renal insufficiency, Parkinson's disease and amyotrophic lateral sclerosis. J Neurol Sci 1981; 51: 437-446. (Pubitemid 11053247)
80. Vinceti M, Guidetti D, Pinotti M, et al. Amyotrophic lateral sclerosis after long-term exposure to drinking water with high selenium content. Epidemiology 1996; 7: 529-532. (Pubitemid 26277700)
81. Voss H. Progressive Bulbärparalyse und amyotrophische Lateralsklerose nach chronischer Manganvergiftung. Arch Gewebepath Gewebehyg 1939; 9: 464-476.
82. Yase Y, Kumamoto T, Yoshimasu F, et al. Amyotrophic lateral sclerosis studies using neutron activation analysis. Neurology India 1968; 16: 46-50.
83. Yoshimasu F, Vebeyashi Y, Yase Y, et al. Studies on amy-otrophic lateral sclerosis by neutron activation analysis. Folia Psychiat Neurol Jpn 1976; 30: 49-55.
84. Yoshimasu F, Yasui M, Yase Y, et al. Studies on amy-otrophic lateral sclerosis by neutron activation analysis. 2. Comparative study of analytical results on Guam PD, Japanese ALS and Alzheimer disease cases. Folia Psychiatry Neurol Jpn 1980; 34: 75-82. (Pubitemid 10042573)
85. Yoshimasu F, Yasui M, Yase Y, et al. Studies on amy-otrophic lateral sclerosis by neutron activation analysis. 3. Systematic analysis of metals on Guamian ALS and PD cases. Folia Psychiatr Neurol Jpn 1982; 36: 173-180.
86. Miyata S, Nakamura S, Nagata H, et al. Increased manganese level in spinal cords of amyotrophic lateral sclerosis determined by radiochemical neutron activation analysis. J Neurol Sci 1983; 61: 283-293. (Pubitemid 13012020)
87. Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharmacol 1837; 1: 41-42.
88. Cotzias GC, Horiuchi K, Fuenzalida S, et al. Chronic manganese poisoning. Clearance of tissue manganese concentrations with persistence of the neurological picture. Neurology 1968; 18: 376-382.
89. Meyers KR, Dorencamp DG, Suzuki K. Amyotrophic lateral sclerosis with diffuse neuroibrillary changes. Arch Neurol 1974; 30: 84-89.
90. Crapper DR, Krishman SS, Quittkat S. Aluminium, neu-roibrillary degeneration and Alzheimer's disease. Brain 1976; 99: 67-80.
91. Klatzo I, Wisniewski H, Streicher E. Experimental production of neuroibrillary degeneration. 1. Light microscopic observations. J Neuropath Exp Neurol 1965; 24: 187-199.
92. Yates CM, Gordon A, Wilson H. Neuroibrillary degeneration induced in the rabbit by aluminium chloride: aluminium neurofibrillary tangles. J Neuropathol Appi Neurobiol 1976; 2: 131-144.
93. De-Boni U, Otros A, Scott JW, et al. Neurofibrillary degeneration induced by systemic aluminium. Acta Neuropathol (Berlin) 1976; 35: 285-294.
94. Hirano A. Progress in the pathology of motor neurone disease. Prog Neuropathol 1973; 2: 181-215.
95. Garruto, RM, Swyt C, Fiori CE, et al. Intraneuronal deposition of calcium and aluminium in amyotrophic lateral sclerosis of Guam. Lancet 1985; ii: 1353. (Pubitemid 16175431)
96. Kjellin KG. The CSF iron in patients with neurological diseases. Acta Neurol Scand 1967; 43: 299-313.
97. Mitchell JD, East BW, Harris IA, Pentland B. Manganese, selenium and other trace elements in spinal cord, liver and bone in motor neurone disease. Eur Neurol 1991; 31: 7-11.
98. Schanne FAY, Kane AB, Young EE, et al. Calcium dependence of toxic cell death: a final common pathway. Science 1979; 206: 700-702. (Pubitemid 10203221)
99. Hochberg FH, Bryan JA, Whelan MA. Clustering of amyotrophic lateral sclerosis. Lancet 1974; i: 34.
100. Melmed C, Krieger C. Clustering of amyotrophic lateral sclerosis. Arch Neurol 1982; 39: 595-596.
101. Taylor JA, Davis JP. Evidence for clustering of amyotrophic lateral sclerosis in Wisconsin. J Clin Epidemiol 1989; 42: 569-575. (Pubitemid 19161021)
102. Sienko DG, Davis JP, Taylor JA, et al. Amyotrophic lateral sclerosis. A case control study following detection of a cluster in a small Wisconsin community. Arch Neurol 1990; 47: 38-41. (Pubitemid 20024151)
103. Proctor SP, Feldman RG, Wolf PA, et al. A perceived cluster of amyotrophic lateral sclerosis in a Massachusetts community. Neuroepidemiology 1992; 1: 277-281. (Pubitemid 23044216)
104. Armon C, Daube JR, O'Brien PC, et al. When is an apparent excess of neurologic cases epidemiologically significant? Neurology 1991; 41: 1713-1718.
105. Mitchell JD, Gibson HN, Gatrell AC. Amyotrophic lateral sclerosis in Lancashire and South Cumbria 1976-86. Arch Neurol 1990; 47: 875-880. (Pubitemid 20251718)
106. Mitchell JD, Gatrell AC, Al-Hamad A, et al. Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and South Cumbria. J Neurol Neurosurg Psychiatry 1998; 65: 842-847. (Pubitemid 128710423)
107. Hyser CL, Kissel JT, Mendell JR. Three cases of amyotrophic lateral sclerosis in a common occupational environment. J Neurol 1987; 234: 443-444.
108. Chad D, Mitsumoto H, Adelman LS, et al. Conjugal motor neurone disease. Neurology 1982; 32: 306-307.
109. Camu W, Cadilhac J, Billiard M. Conjugal amyotrophic lateral sclerosis: a report on two couples from southern France. Neurology 1994; 44: 547-548. (Pubitemid 24098160)
110. Poloni M, Micheli A, Facchetti D. Conjugal amyotrophic lateral sclerosis: toxic clustering or chance? Ital J Neurol Sci 1997; 18: 109-112. (Pubitemid 127757480)
111. Martyn CN, Osmond C. The environment in childhood and risk of motor neuron disease. J Neurol Neurosurg Psychiat 1992; 55: 997-1001.
112. Mitchell JD, Davies RB, Al-Hamad A, et al. MND risk factors: an epidemiological study in the North West of England. J Neurol Sci 1995; 129 (suppl): 61-64.
113. Gajdusek DC, Salazar AM. Amyotrophic lateral sclerosis and Parkinsonian syndromes in high incidence among the Auyw and Jakai people of West New Guinea. Neurology 1982; 32: 107-126. (Pubitemid 12223992)
114. McGeer PL, Schwab C, McGeer EG, Haddock RL, Steele JC. Familial nature and continuing morbidity of the amy-otrophic lateral sclerosis-Parkinsonism dementia complex of Guam. Neurology 1997; 49: 400-409. (Pubitemid 27368873)
115. Eizirik DL, Spencer P, Kisby GE. Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. Biochem Pharmacol 1996; 51: 1585-1591. (Pubitemid 26176727)
116. Iwata S, Sasajima K, Yase Y, et al. Studies of amyotrophic lateral sclerosis by neutron activation analysis and X-ray microanalysis. Ann Rep Res Reactor Inst Kyoto Univ 1976; 9: 44-54.
117. Yanagihara R, Garruto RM, Gajdusek DC, et al. Calcium and vitamin D metabolism in Guamian Chamorros with amyotrophic lateral sclerosis and Parkinsonism-dementia. Ann Neurol 1984; 15: 42-48. (Pubitemid 14224218)
118. Yase Y. Metal studies of ALS. Further development. In: Tsubaki T, Yase Y, eds. Amyotrophic Lateral Sclerosis: Recent advances in research and development. Amsterdam: Excerpta Medica, 1988: 59-65.
119. Mayor GH, Remedi RF, Sprague SM, et al. Central nervous system manifestations of aluminium: effect of parathormone. Neurotoxicology 1980; 1: 33-42. (Pubitemid 11217730)
120. Nakagawa S, Yoshida S, Suematsu C, et al. The calcium-magnesium deicient rat: a study on the distribution of calcium in the spinal cord using the electron probe micro-analyser. Experientia 1977; 33: 1225-1226. (Pubitemid 8175827)
121. Zhang ZX, Anderson DW, Mantel N, Roman GC. Motor neuron disease on Guam: geographic and familial occurrence 1956-85. Acta Neurol Scand 1996; 94: 51-59. (Pubitemid 26276200)
122. Yoshida S, Uebayashi Y, Kihira T, et al. Epidemiology of motor neuron disease in the Kii peninsula of Japan, 1989-1993: active or disappearing focus? J Neurol Sci. 1998; 155: 146-155. (Pubitemid 28139013)
123. Kondo K. Epidemiology of motor neuron disease. In: Leigh PN, Swash M, eds. Motor Neuron Disease: Biology and management. London: Springer, 1995: 19-33.
124. Spencer PS, Allen CN, Kisby GE, et al. Lathyrism and Western Paciic amyotrophic lateral sclerosis: etiology of short and long latency motor system disorders. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. (Advances in Neurology, Vol. 56). New York: Raven Press 1991, pp. 287-310.
125. Tylleskar T, Banea M, Bikanji N, et al. Cassava cyanogens and konzo, an upper motor neuron disease found in Africa. Lancet 1992; 339: 208-211.
126. Camu W, Khoris J, Moulard B, et al. Genetics of familial ALS and consequences for diagnosis. J Neurol Sci 1999; 165: S21-S26. (Pubitemid 29339554)
127. Mitchell JD, Gatt JA, Phillips TM, et al. Cu/Zn superoxide dismutase, free radicals and motoneuron disease. Lancet 1993; 342: 1051-1052. (Pubitemid 23314818)
128. Shaw IC, Fitzmaurice PS, Mitchell JD, Lynch PG. Amy-otrophic lateral sclerosis: a defect in cellular free radical protection mechanisms. Neurodegeneration 1995; 4: 391-396. (Pubitemid 26016927)
129. Liu Y, Brooks BR, Taniguchi N, et al. CuZnSOD and MnSOD immunoreactivity in brain stem motor neurons from amyotrophic lateral sclerosis patients. Acta Neu-ropathol (Berl) 1998; 95: 65-70.
130. Parboosingh JS, Rouleau GA, Meninger V, et al. Absence of mutations in the Mn superoxide dismutase or catalase genes in familial amyotrophic lateral sclerosis. Neuromuscular Disorders 1995; 5: 7-10.
131. Robbins JH, Otsuka F, Tarone RE, et al. Parkinson's disease and Alzheimer's disease: hypersensitivity to X rays in cultured cell lines. J Neurol Neurosurg Psychiatry 1985; 48: 916-923. (Pubitemid 15021659)
132. Mithal NP, Radunovic A, Figlewicz DA, McMillan TJ, Leigh PN. Cells from SOD-1 associated amyotrophic lateral sclerosis do not have an increased susceptibility to radiation-induced free radical production or DNA damage. J Neurol Sci 1999; 164: 89-92. (Pubitemid 29256080)
133. Glenn SA, Ross MA. Delayed radiation-induced bulbar palsy mimicking ALS. Muscle & Nerve 2000; 5: 814-817. (Pubitemid 30256616)
134. Drachman DB, Chaudry V, Cornblath D, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994; 35: 142-150. (Pubitemid 24050149)
135. Berger MM, Kopp N, Vital C, et al. Detection and cellular localisation of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000; 54: 20-25. (Pubitemid 30038732)